BackJounce Therapeutics Overview

Jounce Therapeutics Minority Interest

Latest minority interest for JNCE: $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

Jounce Therapeutics Minority Interest History

Loading

Jounce Therapeutics vs. peers: Minority Interest Comparison

Loading

Jounce Therapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Jounce Therapeutics (JNCE) FAQ

Jounce Therapeutics (JNCE) currently reports a minority interest of $0 as of December 2022. In the prior-year period, the figure was $0. Use the charts on this page to explore Jounce Therapeutics's minority interest history and peer comparisons.

Jounce Therapeutics's minority interest changed from $0 to $0 (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jounce Therapeutics reported $0 in minority interest as of December 2022. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current minority interest of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Jounce Therapeutics, and consider following JNCE for alerts when major investors trade the stock.

Jounce Therapeutics is classified in the Healthcare sector. On minority interest, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JNCE with unrelated industries.